We evaluated the effectiveness of a low-intensity, home-based physical activity program (Onco-Move) and a moderate-to high-intensity, combined supervised resistance and aerobic exercise program (OnTrack) versus Usual Care in maintaining or enhancing physical fitness, minimizing fatigue, enhancing health-related quality of life, and optimizing chemotherapy completion rates in patients undergoing adjuvant chemotherapy for breast cancer.
INTRODUCTION
Adjuvant chemotherapy improves breast cancer survival 1 but can also lead to fatigue, muscle wasting, and reduced physical fitness. 2 This, in turn, can have a negative impact on activities of daily living, social interaction, and health-related quality of life. 3 Previous studies have demonstrated that exercise programs can have a salutary effect on cardiorespiratory fitness, muscle strength, fatigue, mood, health-related quality of life, and immune function [4] [5] [6] [7] [8] [9] [10] and possibly on chemotherapy completion rates. 11 Previous studies have used a wide range of exercise types and intensities. 10 It has been hypothesized that home-based, low-intensity programs may be easier for patients to follow during chemotherapy, 12 whereas higher intensity, supervised exercise programs that incorporate resistance training and aerobic exercise may be most effective. 4, 13 To our knowledge, no study has yet made a head-to-head comparison of these two types of programs.
The primary aim of our study was to evaluate the effectiveness of a home-based, lowintensity physical activity program (Onco-Move) and a supervised, moderate-to highintensity, combined resistance and aerobic exercise program (OnTrack) in maintaining or enhancing physical fitness and minimizing fatigue in patients undergoing adjuvant chemotherapy. In addition, we hypothesized that both interventions would result in higher levels of physical activity and functioning in daily life, less psychological distress, and better health-related quality of life. We expected greater gains in cardiorespiratory fitness and muscle strength for participants in the OnTrack versus the Onco-Move program. Finally, we hypothesized a positive effect of both interventions on chemotherapy completion rates (i.e., the percentage of patients who would complete chemotherapy without dose adjustments).
PATIENTS AND METHODS

Research design and study sample
The Physical Exercise During Adjuvant Chemotherapy Effectiveness Study (PACES) was a randomized, controlled, multicenter trial with two intervention groups and a Usual Care control group. Patients were eligible for the trial if they had histologically confirmed primary breast or colon cancer and were scheduled to undergo adjuvant chemotherapy at one of 12 hospitals in the Amsterdam region of the Netherlands. 14 Patients were excluded if they had serious orthopedic, cardiovascular, or cardiopulmonary conditions, were suffering from malnutrition, had serious psychiatric or cognitive problems, or did not have basic fluency in Dutch. There was no upper age limit. Institutional review boards of all participating hospitals approved the study.
Procedure
Potentially eligible patients with breast cancer were identified through hospital records, whereas patients with colon cancer were identified by their treating physicians. After providing informed consent and completing baseline assessments, patients were randomly assigned to Onco-Move, OnTrack, or Usual Care using the minimization method, 15 which balanced groups with respect to age, primary diagnosis, treating hospital, and use of trastuzumab.
Interventions
Onco-Move is a home-based, low-intensity, individualized, self-managed physical activity program, as proposed by Mock, 12 to which behavioral reinforcement techniques were added in this study. These comprised written information that was tailored to the individual's preparedness to exercise according to the Transtheoretical model, 16 and an activity diary that was discussed at each chemotherapy cycle. Specially trained nurses encouraged participants to engage in at least 30 minutes of physical activity per day, five days per week, with an intensity level of 12 to 14 on the Borg scale of perceived exertion. 17 OnTrack is a moderate-to high-intensity, combined resistance and aerobic exercise program and was supervised by specially trained physical therapists. 18 The participants attended two sessions per week. Six large muscle groups were trained for 20 minutes per session, with two series of eight repetitions at 80% of the one repetition maximum. One repetition maximum testing was repeated every three weeks. Each session incorporated 30 minutes of aerobic exercises, with an intensity of 50% to 80% of the maximal workload as estimated by the steep ramp test. 19 The intensity was adjusted using the Borg scale, with a threshold of less than 12 for increase and more than 16 for decrease of intensity. 17 Participants in this group were also encouraged to be physically active five days each week for 30 minutes per session and to keep an activity diary. Both interventions started with the first cycle of chemotherapy and continued until three weeks after the last cycle.
Usual Care varied according to hospital guidelines and preferences, but did not involve routine exercise.
Timing of assessments and study measures
Patients underwent performance-based tests and completed questionnaires at three points in time: baseline, before random assignment and start of chemotherapy, at completion of chemotherapy, and six months after completion of chemotherapy.
Primary outcomes were cardiorespiratory fitness, muscle strength, and fatigue. Cardiorespiratory fitness was assessed with the steep ramp test 19 and an endurance test at 70% of the estimated maximal workload, 14 muscle strength with the microFET® hand held dynamometer (Hoggan Health, Salt Lake City, UT) for elbow flexion 20 and knee extension 21 and the Jamar grip strength dynamometer (Lafayette Instrument, Lafayette, IN), 22 and lowerlimb muscle endurance with the 30-s chair stand test. 23 Fatigue was measured with the Multidimensional Fatigue Inventory 24 and the Fatigue Quality List. 25 The secondary outcomes included self-reported physical activity level, 26 functioning in daily life, 27 quality of sleep, 28 psychological distress, 29 health-related quality of life, 30 return to work, and chemotherapy completion rates (see Table 1 and van Waart et al. 14 and Chinapaw et al. 31 ). 
Statistical analyses
With more than 64 participants per group, the study had 80% power to detect an effect size of 0.5, with a two-tailed P value set at 0.05. 32 Scores on the Multidimensional Fatigue Inventory, Fatigue Quality List, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), Hospital Anxiety and Depression Scale, Sleep Quality Inventory, Impact on Participation and Autonomy, and Physical Activity Scale for the Elderly were calculated according to published scoring algorithms.
Generalized estimating equations analysis with an exchangeable correlation structure was used to simultaneously evaluate the effects of the interventions at end of chemotherapy and 6-month follow-up. This statistical technique adjusts for the non-independence of observations over time. We entered group, time, and the interaction of group x time as independent variables into the regression model, adjusting for baseline values. 33 Mean differences and 95% confidence levels were accompanied by effect sizes. 34 Effect sizes of 0.2 were considered small, 0.5 moderate and clinically relevant, and 0.8 large. 27, 30 Group differences in chemotherapy completion rates were analyzed with binary logistic regression analysis; dose reduction during the period of chemotherapy treatment (the period between baseline and end of chemotherapy) was the dependent variable.
We provide descriptive data and 95% confidence intervals for all comparisons, and significance tests (P values) for hypothesized comparisons only. All analyses were conducted on an intention-to-treat basis. 
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RESULTS
Between March 2010 and December 2012, 230 of 524 eligible patients with breast cancer (44%) were recruited for the study. Reasons for nonparticipation are shown in Figure 1 . During the study period, only 63 patients with colon cancer were referred to the study, 23 of whom were successfully recruited. As a result of the small number of patients with colon cancer, this analysis is restricted to patients with breast cancer. Because we stratified by primary diagnosis, the success of the random assignment process was not affected by the exclusion of patients with colon cancer.
Study nonparticipants had a significantly lower educational level (P = 0.006) and were significantly less likely to be working (P < 0.001) than participants. There were no other significant differences in background characteristics between participants and nonparticipants.
Participants had a mean age of 51 years, 55% had a college or university degree, and 68% were employed. Most participants had stage II (47%) or III breast cancer (46%). Approximately three fourths of the participants underwent breast-conserving surgery, approximately 30% had an axillary lymph node dissection, and approximately 75% received radiotherapy. Baseline characteristics were balanced across groups (Table 2) . 
Between-Group difference T1
Between-Group difference T2 Table 3 . Mean values at baseline (T0), end of chemotherapy (T1) and six month follow-up (T2) and between group differences for objective performance measures NOTE: Bold font indicates significant difference. Abbreviations: AMD, adjusted mean difference between groups; ES, effect size of difference between groups; HHD, handheld dynamometer; SD, standard deviation; T0, baseline before chemotherapy; T1, at completion of chemotherapy; T2, six months after completion of chemotherapy; UC, Usual Care. Maximal short exercise capacity (Watts) 
Between-Group difference T2 Table 5 . Mean values at baseline (T0), end of chemotherapy (T1) and six month follow-up (T2) and adjusted between group differences secondary outcome measures
On average, participants in OnTrack attended 71% of the planned sessions. On the basis of the exercise diary, 48% of the OnTrack group and 55% of the Onco-Move group followed the recommendations regarding daily activity levels at least 75% of the time. Outcome data were available for 204 participants (89%) directly after chemotherapy, and for 196 (85%) at the 6-month follow-up. In the remainder of the article we will use the terms OnTrack, OncoMove, and Usual Care to denote the participants in those groups.
Cardiorespiratory fitness, muscle strength, and fatigue
Data on cardiorespiratory fitness, muscle strength, and fatigue are shown in Tables At 6-month follow-up, no significant between-group differences were observed for any of the performance-based measures of physical fitness or in self-reported fatigue.
Health-related quality of life, symptom burden, and return to work
At the end of chemotherapy, both OnTrack and Onco-Move reported significantly better physical functioning (ES = 0.81 and 0.68, respectively), less nausea and vomiting (ES = 0.89 and 1.00), and less pain (ES = 0.46 and 0.60) than Usual Care. In addition, OnTrack reported significantly better cognitive functioning (ES = 0.32) than Usual Care and less constipation compared with Usual Care and Onco-Move (ES = 0.98 and 0.61, respectively). Onco-Move reported significantly less fatigue on the basis of the EORTC QLQ-C30 scale (ES = 0.51) than Usual Care (Table 5) .
At 6-month follow-up, OnTrack and Onco-Move reported significantly better social functioning (ES = 0.42 and 0.35), whereas only OnTrack reported significantly less pain (ES = 0.36) than Usual Care. There were no other significant group differences at the end of chemotherapy or 6-month follow-up for the remaining EORTC QLQ-C30 scales or the measures of psychological distress (Hospital Anxiety and Depression Scale), functioning in daily life (Impact on Participation and Autonomy instrument), quality of sleep (Pittsburgh Sleep Quality Index) or self-reported activity level (Physical Activity Scale for the Elderly; data not shown).
At the end of chemotherapy, significantly more patients in OnTrack (34%) and OncoMove (40%) were working than in Usual Care (15%; P = 0.010). At 6-month follow-up, both intervention groups had significantly higher return to work rates than Usual Care (83% and 79% versus 61%; P = 0.012 for both comparisons), and worked a significantly higher percentage of the pre-illness hours on the job than Usual Care (59% and 60% versus 42%; P = 0.014 for both comparisons). Physical health limitations were reported more frequently as the reason for not returning to work by Usual Care (41%) than either OnTrack (25%) or OncoMove (27%).
Chemotherapy and trastuzumab completion Rates
Information on chemotherapy and trastuzumab completion rates is shown in Table 6 . The planned chemotherapy regimens and schedules of the three groups were similar and included combinations of anthracyclines, taxanes, alkylating agents, and antimetabolites. In total, 61 patients required chemotherapy dose adjustments. The main reason for adjustment was neuropathy (31%; Table 6 ).
A significantly smaller percentage of OnTrack (12%) required dose adjustments in the prescribed chemotherapy regimen than Usual Care (34%) or Onco-Move (34%; odds ratio (OR) = 0.26; P = .002), indicating about a fourfold lower likelihood of dose adjustment; 95% CI: 0.11 to 0.61 for both comparisons). The average dose reduction among those who required chemotherapy adjustment in OnTrack and Onco-Move was 10%, compared with 25% in Usual Care (mean difference, -0.15; 95% CI: -2.96 to -0.01; P = 0.014).
In an exploratory analysis, we examined trastuzumab completion rates and left ventricular ejection fractions. Sixty-five patients, distributed equally across the study groups, received trastuzumab during and after their chemotherapy. There were no statistically significant differences between the groups (P = 0.16). Six percent of the patients in OnTrack required delay or discontinuation of trastuzumab treatment because of reduced left 
DISCUSSION
The results of this trial support our hypothesis that moderate-to high-intensity exercise during chemotherapy (OnTrack) has a beneficial effect on cardiorespiratory fitness, muscle strength, fatigue, and chemotherapy completion rates. Salutary effects were also found for symptom burden (e.g., nausea and vomiting, pain, constipation) and return to work. The effects of low-intensity physical activity were less pronounced (except for nausea) and were limited to measures of endurance, symptom burden, and return to work.
The observed intervention effects did not reflect improvement in physical fitness levels or fatigue during chemotherapy, but rather a less steep decline or a stable situation. Similar results have been reported in earlier exercise trials in breast cancer, 9, 11, 31, 32 with only one trial of high-intensity resistance training reporting improvement over time in muscle strength. 9 Most of the positive effects of the interventions were limited to the period during which the patients were receiving chemotherapy. At 6-month follow-up, all groups had returned to approximately their baseline (i.e., pre-chemotherapy) levels of physical fitness and fatigue. This does not detract from the efficacy of the interventions in that they were designed primarily to minimize decline in, if not enhance, fitness and to reduce symptom burden during the period of active treatment. We would emphasize that a return to baseline levels at 6-month follow-up does not necessarily imply that the patients had returned to their pre-illness fitness levels. Our baseline assessments took place after patients had undergone surgery and, in most cases, radiotherapy. Previous studies have reported a decline in physical fitness and functioning levels after surgery and/or radiotherapy. 38 Thus, it is likely that participants in our study had not returned to their pre-illness levels of physical health, and therefore might still benefit from participating in physical rehabilitation programs after completion of treatment.
Patients who participated in a physical exercise or activity program were more likely to have returned to work at 6-month follow-up than those in Usual Care. This not only has financial implications, but also carries meaning in terms of quality of life and a sense of return to normalcy. 39 To the best of our knowledge, our study is the first to replicate the previously observed positive effect of moderate-to high-intensity exercise on chemotherapy completion rates. We also observed a potential dose-response relationship for exercise on chemotherapy completion rates. 11 OnTrack had substantially higher chemotherapy completion rates than both Onco-Move and Usual Care. However, the amount of dose reduction required among those whose chemotherapy regimen was modified was lower in both intervention groups as compared with Usual Care. We did not have sufficient statistical power for this subgroup analysis; thus, future trials are needed to confirm this finding. These findings have potentially important clinical implications, in that higher chemotherapy completion rates may improve disease-free and overall survival. 1 An exploratory follow-up of the exercise trial by Courneya et al. 11 lends preliminary support to this hypothesis. 40 An interesting finding, albeit one that is based on exploratory analyses, was the trend toward less delay or discontinuation of trastuzumab treatment in the OnTrack group. This might indicate a potential protective effect of exercise against cardiotoxicity. 41 However, we would note that the percentage of patients in OnTrack with delayed or discontinued trastuzumab use was comparable to that reported by de Azambuja et al, 42 whereas the percentage in Onco-Move and Usual Care groups was much higher. Thus, we cannot rule out that our observed differences may reflect a chance finding.
Our study had several limitations that should be noted. First, we were unable to determine peak oxygen uptake directly as a result of limited testing facilities and the small time-window between referral to the trial and start of chemotherapy. Instead, we used the maximal short exercise capacity on the steep ramp test to evaluate changes in cardiorespiratory fitness. The steep ramp test has been shown to be reliable (intraclass correlation coefficient, 0.996) and valid for this purpose. 19 We also added an endurance test, which may be more clinically relevant than maximal short exercise capacity, given that activities in daily living are not performed at peak levels. 43 Second, our study was limited to the effect of exercise during adjuvant chemotherapy. We anticipate that exercise would be equally if not more effective in patients receiving neoadjuvant chemotherapy, because they will not have yet experienced the functional limitations associated with surgery (e.g., on shoulder function). A recent phase II trial showed improved physical fitness and decreased fatigue after aerobic exercise during neoadjuvant chemotherapy. 44 Third, although our recruitment rate was much higher than the anticipated 25%, 14 slightly more than half of the eligible patients declined to participate in the trial. This is a common finding in exercise oncology trials [45] [46] [47] and raises issues regarding the generalizability of results to the larger target population. Those who chose to participate in the trial were more highly educated and more likely to be working than those who did not. This is not unexpected, in that education is correlated positively with health literacy, and those who are health literate may be more open to advice about being physically active during treatment. 48 Future studies are needed to better understand the practical and attitudinal barriers to being physically active both during and after cancer treatment, and to develop appropriate, tailored approaches to encourage reluctant patients to become more active.
Finally, although we intended to recruit both patients with breast cancer and colon cancer into our trial, we experienced significant problems in recruiting the latter group. More patients with colon cancer than anticipated were receiving palliative rather than adjuvant chemotherapy, and patients who had undergone major abdominal surgery were typically advised to refrain from intensive physical activity for 6 weeks after surgery. Clinicians were also more hesitant to refer patients with colon cancer to our study. Others have also reported difficulty in recruiting patients with colon cancer into exercise oncology trials, 49 and thus more research is needed to better understand how to modify existing exercise programs to meet the needs of this patient population.
Our study also had a number of strengths, including a direct comparison of home-based, low-intensity and supervised, moderate-to high-intensity exercise programs versus Usual Care, a large sample size, multicenter participation, limited loss to follow-up, and the use of both objective and self-reported outcomes.
In conclusion, our findings indicate that both a moderate-to high-intensity physical exercise program and a low-intensity physical activity program are safe and feasible during adjuvant chemotherapy for breast cancer. The moderate-to high-intensity program was most effective in minimizing decline in cardiorespiratory fitness and muscle strength, limiting fatigue and symptom burden, avoiding the need for chemotherapy dose reduction, and facilitating return to work. The low-intensity program also had significant, positive effects, albeit of a lesser scope and magnitude. In general, we would recommend that women who are able and willing to participate be offered a supervised, moderate-to high-intensity exercise program during adjuvant chemotherapy. For other women, the home-based, lowintensity physical activity program represents a viable alternative.
